Exagen (NASDAQ:XGN – Get Rating) had its price objective decreased by Cowen to $7.00 in a report released on Thursday, Stock Target Advisor reports. Cowen's price objective would suggest a potential upside of 138.10% from the stock's current price.
A number of other research analysts have also recently issued reports on the company. Canaccord Genuity Group reduced their price objective on Exagen from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday. BTIG Research dropped their target price on shares of Exagen from $10.00 to $7.00 and set a "buy" rating for the company in a report on Thursday. KeyCorp lowered shares of Exagen from an "overweight" rating to a "sector weight" rating in a report on Friday, August 5th. Finally, Canaccord Genuity Group dropped their target price on shares of Exagen from $8.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Exagen has an average rating of "Moderate Buy" and an average target price of $9.60.
Get Exagen alerts:Exagen Stock Down 4.2 %
Shares of NASDAQ:XGN opened at $2.94 on Thursday. The stock's 50-day moving average price is $2.92 and its 200-day moving average price is $4.79. Exagen has a 12-month low of $2.10 and a 12-month high of $12.89. The stock has a market capitalization of $47.80 million, a P/E ratio of -1.30 and a beta of 1.17. The company has a current ratio of 9.30, a quick ratio of 9.30 and a debt-to-equity ratio of 0.43.
Institutional Investors Weigh In On Exagen
Several institutional investors and hedge funds have recently made changes to their positions in the company. HighTower Trust Services LTA bought a new stake in shares of Exagen during the 2nd quarter valued at $231,056,000. Stonepine Capital Management LLC grew its position in shares of Exagen by 0.4% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,265,373 shares of the company's stock valued at $3,429,000 after acquiring an additional 4,986 shares during the period. RTW Investments LP grew its position in shares of Exagen by 2.3% during the 3rd quarter. RTW Investments LP now owns 1,048,662 shares of the company's stock valued at $2,842,000 after acquiring an additional 23,660 shares during the period. Perkins Capital Management Inc. grew its position in shares of Exagen by 8.6% during the 3rd quarter. Perkins Capital Management Inc. now owns 257,455 shares of the company's stock valued at $698,000 after acquiring an additional 20,480 shares during the period. Finally, Cooper Creek Partners Management LLC bought a new stake in shares of Exagen during the 1st quarter valued at $1,232,000. Institutional investors own 65.94% of the company's stock.Exagen Company Profile
(Get Rating)
Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
See Also
- Get a free copy of the StockNews.com research report on Exagen (XGN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.